Clinical Trials Logo

Filter by:
NCT ID: NCT05809362 Completed - Atrial Fibrillation Clinical Trials

WHOOP Abnormal Rhythm Notification

WARN
Start date: April 10, 2023
Phase:
Study type: Observational

The purpose of this protocol is to assess the sensitivity and specificity of a photoplethysmography (PPG)-based algorithm for the detection of atrial fibrillation as compared to a gold-standard assessment (wearable ECG patch) among a population of individuals with known atrial fibrillation and without known atrial fibrillation over a 7-day study period.

NCT ID: NCT05808257 Completed - Nephrolithiasis Clinical Trials

Thulium vs. Hol:YAG Laser

Start date: January 7, 2022
Phase: N/A
Study type: Interventional

This is a randomized prospective study to compare stone free rates and operative efficiency of two laser systems used during retrograde intrarenal surgery for kidney stone disease: 1. A superpulsed thulium fiber laser (thulium) 2. A pulse modulated high power holmium laser (Holmium)

NCT ID: NCT05808127 Completed - Pain Clinical Trials

Guiding Aging Long-Term Opioid Therapy Users Into Safer Use Patterns

Start date: August 9, 2023
Phase: N/A
Study type: Interventional

Patients on long-term opioid therapy are aging and now face magnified risk of harm with continued high-dose opioid use. These increased risks are due to age-related changes in drug metabolism, multi-morbidity, and polypharmacy. The dominant approach to mitigate these risks is to screen for aberrant patient opioid behaviors so that clinicians can pre-empt misuse early through review of contractual opioid agreements or by lowering patient dosages. By focusing on opioid misuse alone, this strategy encourages forced opioid tapering that is associated with opioid overdose and mental health crisis. Directing clinician attention to the comorbid conditions associated with opioid misuse may promote safer and more effective care. The objective of this study is to assess the comparative effectiveness of PainTracker, a set of questions that targets a broad range of problems associated with pain, in a randomized controlled trial involving 300 Northwestern Medicine clinicians treating Chronic Opioid Use Registry patients (n=5159).

NCT ID: NCT05807620 Completed - Wrinkle Clinical Trials

A 12 Week Study to Evaluate the Efficacy of an Eye Cream

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

This single center, open-label clinical study was conducted to assess the efficacy and tolerance of a topical eye cream when used over the course of 12 weeks by healthy women with moderate to severe under-eye dark circles, moderate under eye puffiness, and mild fine lines and wrinkles. A total of 37 subjects were enrolled into the study.

NCT ID: NCT05807412 Completed - Rhytides Clinical Trials

Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides

Start date: May 1, 2023
Phase: Early Phase 1
Study type: Interventional

Ten subjects will be enrolled in the study. Each subject will have their left and right forehead randomly assigned to receive 4 units of PrabotulinumtoxinA-xvfs or OnabotulinumtoxinA. Subjects will be reassessed at 2 weeks for evaluation of rhytide diminution around each injection point to assess relative diffusion of each drug in the forehead.

NCT ID: NCT05806788 Completed - Binge Eating Clinical Trials

Binge Eating Syndrome Treatment for Older Women (BESTOW)

BESTOW
Start date: February 17, 2023
Phase: N/A
Study type: Interventional

Twenty women, ages 60 or older, will be consented and enrolled in a single-arm, pilot implementation trial of the age-tailored cognitive-behavioral based BE intervention. Participants will complete assessments at baseline, post-intervention, and at two follow-up timepoints; weekly BE frequency will be collected to monitor progress during the intervention period.

NCT ID: NCT05806567 Completed - Clinical trials for Immune System Disorder (Healthy Volunteers)

A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

Start date: July 27, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety and pharmacokinetics (PK) effect of belumosudil on the uridine diphosphate glucuronosyltransferase (UGT)1A1 (Part 1), P glycoprotein (P-gp) (Part 2) and breast cancer resistance protein (BCRP)/organic anion transporting polypeptide (OATP)1B1 (Part 3) inhibition in the fed state in healthy male subjects.

NCT ID: NCT05806359 Completed - Healthy Volunteers Clinical Trials

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants

Start date: March 31, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, and single-dose pharmacokinetics of danicamtiv in healthy Japanese and Caucasian participants.

NCT ID: NCT05806268 Completed - Clinical trials for BRAF v600 Mutated Metastatic Melanoma

Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients

Start date: July 30, 2021
Phase:
Study type: Observational

This was a retrospective real-world evidence cohort study. The study was conducted using the NOBLE (Novartis Braf+ meLanoma patients ObsErvational) dataset, with a study period from 01 January 2011 to 31 May 2020. All included patients were ≥18 years of age and were required to have a diagnosis of unresectable stage III or IV melanoma (ICD-9 172.x & ICD-10 C43 or D03x), treatment with dabrafenib and trametinib (dab/tram) or encorafenib and binimetenib (enco/bini) on or after 01 June 2018, and evidence of a BRAF-positive result prior to or up to 30 days after therapy initiation. No quota of centers was established a priori. Given the retrospective nature of this study, all patients who met the inclusion/exclusion criteria from the NOBLE dataset were included.

NCT ID: NCT05805865 Completed - Clinical trials for Gingival Inflammation

Efficacy of Eco-Friendly Toothpaste Tablets Versus Conventional Toothpaste Using PI and GI Index

Start date: January 3, 2023
Phase: N/A
Study type: Interventional

Objectives: To assess the change in gingival index (GI) and plaque index (PI) when comparing the use of toothpaste tablets to conventional toothpaste. Methods: 40 participants were randomized into two groups: Colgate's toothpaste tablets (T) and Colgate's Cavity Protection toothpaste (C). Both groups utilized their assigned dentifrice for 2 weeks. A pre and post-assessment measured the GI and PI index. A questionnaire on the use of the product was distributed.